Therapy Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Aldesleukin	Proleukin	IL-2\|Interleukin-2\|IL2		Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).

Showing 1 to 1 of 1 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
No data available in table

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 34 of 34 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT00338377	Phase II	Cyclophosphamide + Fludarabine Aldesleukin	Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma	Active, not recruiting	USA	0
NCT01038778	Phase Ib/II	Entinostat Aldesleukin	Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer	Active, not recruiting	USA	0
NCT01659151	Phase II	Aldesleukin Fludarabine Vemurafenib	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma	Active, not recruiting	USA	0
NCT01701674	Phase I	Cyclophosphamide + Fludarabine Ipilimumab Aldesleukin	Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts	Active, not recruiting	USA	0
NCT01857934	Phase II	Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan	Therapy for Children With Advanced Stage Neuroblastoma	Active, not recruiting	USA	0
NCT03126916	Phase III	Doxorubicin 131I-MIBG Sargramostim Etoposide Melphalan Busulfan Isotretinoin Vincristine Sulfate Cisplatin Cyclophosphamide Thiotepa Dexrazoxane Lorlatinib Carboplatin Aldesleukin Topotecan Dinutuximab	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)	Active, not recruiting	USA \| CAN	1
NCT05628883	Phase I	Cyclophosphamide + Fludarabine TBio-4101 Aldesleukin	Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma	Active, not recruiting	USA	0
NCT01258855	Phase II	Aldesleukin Aflibercept	Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	Completed	USA	0
NCT01593670	Phase II	Decitabine Aldesleukin Vorinostat	Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes	Completed	USA	0
NCT01993719	Phase II	Pembrolizumab Aldesleukin Fludarabine Cyclophosphamide	Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma	Completed	USA	0
NCT02027935	Phase II	Aldesleukin Cyclophosphamide Ipilimumab	Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4	Completed	USA	0
NCT02118285	Phase I	Aldesleukin Epacadostat Cyclophosphamide Fludarabine	Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Completed	USA	0
NCT02620865	Phase Ib/II	Paclitaxel Aldesleukin Oxaliplatin Sargramostim Gemcitabine Fluorouracil + Leucovorin	Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Completed	USA	0
NCT03056599	Phase I	Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel	Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma	Completed	USA	0
NCT03215810	Phase I	Nivolumab tumor infiltrating lymphocytes Cyclophosphamide + Fludarabine Aldesleukin	Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer	Completed	USA	0
NCT03224871	Phase I	Pembrolizumab Aldesleukin Nivolumab	A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.	Completed	USA	0
NCT03441100	Phase I	Cyclophosphamide + Fludarabine Aldesleukin IMA202	TCR-engineered T Cells in NSCLC and HCC Patients	Completed	USA \| DEU	0
NCT01174121	Phase II	Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Recruiting	USA	0
NCT02621021	Phase II	Pembrolizumab Cyclophosphamide Fludarabine Aldesleukin	A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab	Recruiting	USA	0
NCT03166397	Phase II	Cyclophosphamide + Fludarabine Aldesleukin Nivolumab tumor infiltrating lymphocytes Ipilimumab	Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients	Recruiting	ISR	0
NCT03190941	Phase Ib/II	Cyclophosphamide anti-KRAS G12V mTCR cells Fludarabine Aldesleukin	Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Recruiting	USA	0
NCT03991741	Phase I	Aldesleukin	Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors	Recruiting	USA	0
NCT05681780	Phase Ib/II	Cyclophosphamide + Fludarabine Aldesleukin Nivolumab CD40L-augmented TILs	Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC	Recruiting	USA	0
NCT05883449	Phase II	AB-101 + AFM13 Aldesleukin Cyclophosphamide + Fludarabine	Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)	Recruiting	USA	0
NCT06151847	Phase II	Cyclophosphamide + Fludarabine Lifileucel Aldesleukin	Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma	Recruiting	USA	0
NCT06190249	Phase I	Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna	Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma	Recruiting	USA	0
NCT06236425	Phase I	Cisplatin + Pembrolizumab Aldesleukin Carboplatin + Fluorouracil + Pembrolizumab TBio-4101 Cyclophosphamide + Fludarabine Cisplatin + Fluorouracil + Pembrolizumab	TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC	Recruiting	USA	0
NCT01218867	Phase Ib/II	Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin	Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes	Terminated	USA	0
NCT01409174	Phase Ib/II	Cisplatin Ipilimumab Aldesleukin Temozolomide Interferon alpha-2b	IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma	Terminated	USA	0
NCT01640301	Phase Ib/II	Aldesleukin WT1 sensitized T cells	Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	Terminated	USA	0
NCT02774291	Phase I	Aldesleukin Cyclophosphamide + Fludarabine Filgrastim	Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1	Terminated	USA	0
NCT02796352	Phase II	Aldesleukin	A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study	Terminated	USA	0
NCT03691376	Phase I	Melphalan NY-ESO-1 TCR CD4- CD34+ HSC Aldesleukin Autologous NY-ESO-1-specific CD8-positive T cells	Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Terminated	USA	0
NCT04551885	Phase I	Cyclophosphamide + Fludarabine Avelumab + FT516 Aldesleukin	FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Terminated	USA	0

Showing 1 to 34 of 34 entries

Filter rows:

Therapy Detail

Contact

Filtering

Sorting

Filtering

Sorting

Filtering

Sorting

Additional content available in CKB BOOST